Pyxis Oncology, Inc. · NASDAQ:PYXS

Pyxis Oncology — Technical Presentation (December 2020)

10 slides from Pyxis Oncology's technical presentation, December 2020

  1. Slide 1: PBTC-051: First in pediatrics phase 1 study of APX005M

    PBTC-051: First in pediatrics phase 1 study of CD40 agonistic monoclonal antibody APX005M in pediatric subjects with recurrent/refractory brain tumors Holly Lindsay MD, MS, Arzu Onar-Thomas PhD, Mehmet Kocak PhD, Tina Young Poussaint MD, Girish Dhall MD, Alberto Broniscer MD, Anna Vinitsky MD, Tobey

  2. Slide 2: COI Declaration

    ISPNO 2020 COI Declaration The following presenters have no conflict of interest relating to this presentation with any corporate organizations : Alberto Broniscer Tobey MacDonald Girish Dhall Arzu Onar-Thomas Jason Fangusaro Anna Vinitsky Mehmet Kocak Tina Young Poussaint Holly Lindsay 2

  3. Slide 3: COI Declaration

    ISPNO 2020 COI Declaration The presenter below has potential conflict of interest related to this presentation with the corporate organizations below: Ira Dunkel Consultant, Apexigen Inc. Ovid Trifan CMO and senior vice president, Apexigen Inc. 3

  4. Slide 4: APX005M Mechanism of Action

    APX005M Mechanism of Action  APX005M: CD40 agonist IgG1 humanized monoclonal antibody (Apexigen, Inc.)  CD40: co-stimulatory molecule expressed on antigen presenting cells (APCs)  CD40 functions to: • suppression Reverse systemic cancer-induced immune • Activate immunity APCs → activates innate a

  5. Slide 5: PBTC-051 Study Overview

    PBTC-051 Study Overview First-in-pediatrics evaluation of APX005M by the Pediatric Brain Tumor Consortium APX005 administered IV over 1 hour every 3 weeks for maximum 36 cycles Stratum 1: Patients 1-21 years old with recurrent, refractory, or progressive primary malignant CNS tumors • Patients wi

  6. Slide 6: Study Objectives

    Study Objectives Primary study objectives: • Evaluate safety of APX005M administered IV q3 week to children with CNS tumors • Determine maximum tolerated dose and/or recommended phase 2 dose • Determine APX005M pharmacokinetics Exploratory study objectives • Assess incidence of anti-drug antibodie

  7. Slide 7: Stratum 1 Enrollment

    Stratum 1 Enrollment  21 total patients enrolled on study • 19 patients off treatment for progressive disease • 1 patient off treatment for side effects • 1 patient ineligible Youngest enrolled patient: 2 yo, oldest: 21 yo Most common diagnoses: ependymoma (7 patients) and glioblastoma (5 patient

  8. Slide 8: Stratum 1 APX005M Adverse Events

    Stratum 1 APX005M Adverse Events Most common adverse events: neutropenia (max grade 3) and leukopenia and lymphopenia (max grade 4) 2 dose-limiting toxicities: both grade 3 infusion-related reactions • Both at highest dose level (dose level 3) 1 death on study and 1 death within 1 month off-study

  9. Slide 9: Stratum 1 Results

    Stratum 1 Results  Highest dose level (dose level 3 = 0.6 mg/kg) is stratum 1 pediatric recommended phase 2 doses Total 12 evaluable patients enrolled at dose level 3 in dose escalation and expansion cohorts • For reference, the adult R2PD is DL2=0.3 mg/kg 2 patients received >15 cycles of therap

  10. Slide 10: Acknowledgements

    Acknowledgements NCI/NIH grant UM1 CA081457 supporting the Pediatric Brain Tumor Consortium The American Lebanese Syrian Associated Charities for partial support of the PBTC Operations, Biostatistics and Data Management Core Our patients and their families 11

Pyxis Oncology — Technical Presentation (December 2020) on 6ix